Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 85.6%

Neg 85.6% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.